Contineum Therapeutics (NASDAQ:CTNM) & Bright Minds Biosciences (NASDAQ:DRUG) Critical Comparison

Contineum Therapeutics (NASDAQ:CTNM) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

40.5% of Bright Minds Biosciences shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Contineum Therapeutics and Bright Minds Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	0	0	3	0	3.00
Bright Minds Biosciences	0	0	0	0	N/A

Contineum Therapeutics presently has a consensus price target of $28.67, suggesting a potential upside of 57.60%. Given Contineum Therapeutics’ higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Bright Minds Biosciences.

Profitability

This table compares Contineum Therapeutics and Bright Minds Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	N/A	N/A
Bright Minds Biosciences	N/A	-58.55%	-53.79%

Valuation & Earnings

This table compares Contineum Therapeutics and Bright Minds Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50.00 million	9.36	$22.72 million	N/A	N/A
Bright Minds Biosciences	N/A	N/A	-$5.47 million	($1.01)	-1.23

Contineum Therapeutics has higher revenue and earnings than Bright Minds Biosciences.

Summary

Contineum Therapeutics beats Bright Minds Biosciences on 6 of the 8 factors compared between the two stocks.

About Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

About Bright Minds Biosciences

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.